



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Journal of Infection

journal homepage: www.elsevier.com/locate/jinf

Review

The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19

Qing Ye, Bili Wang, Jianhua Mao*

National Clinical Research Center for Child Health, National Children's Regional Medical Center, the Children's Hospital, Zhejiang University School of Medicine, No 3333, Binsheng Road, Hangzhou 310052, China

ARTICLE INFO

Article history:

Accepted 24 March 2020

Available online xxx

Keywords:

Coronavirus

2019-nCoV

SARS-CoV-2

Cytokine storm

Immunomodulation

SUMMARY

Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment.

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Introduction

Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) emerged for the first time in Wuhan, China, in December 2019. It is a type of highly pathogenic human coronavirus (HCoV) that causes zoonotic diseases and poses a major threat to public health. The vast majority of patients with the coronavirus disease 2019 (COVID-19) have had a good prognosis, but there were still some critical individuals and even deaths.¹

Most of these critically ill and dead patients did not develop severe clinical manifestations in the early stages of the disease. Some of the patients only showed mild fever, cough, or muscle soreness. The conditions of these patients deteriorated suddenly in the later stages of the disease or in the process of recovery. Acute respiratory distress syndrome (ARDS) and multiple-organ failure occurred rapidly, resulting in death within a short time.² Cytokine storm is considered to be one of the major causes of ARDS and multiple-organ failure.³ It plays an important role in the process of disease aggravation.⁴ Clinical studies have detected a cytokine storm in critical patients with COVID-19. Therefore, effectively suppressing the cytokine storm is an important way to prevent the deterioration of patients with COVID-19 infection and save the patients' lives.⁵ This article reviews the mechanisms by which HCoV infection induces cytokine storm and the options to inhibit the cytokine storm, in order to provide a reference for the clinical diagnosis and treatment of COVID-19.

HCoVs

Coronaviruses (CoVs) are single-stranded, positive-strand RNA viruses belonging to the Coronaviridae family, Nidovirales order. The International Committee on Taxonomy of Viruses (ICTV) classifies the CoVs into four categories: α , β , γ , and δ . Under the electron microscope, the virus particles display a rough spherical or multi-faceted crystal shape. The surface of the viruses has prominent club-shaped projections composed of its spike protein. Inside the virus particle is the viral genome wrapped in a nucleocapsid. The viral genome contains approximately 26,000 to 32,000 bases. CoVs are the largest known RNA viruses. The positive-strand viral RNA consists of a cap structure at the 5' end and multiple poly(A) tails at the 3' end. It serves as messenger RNA (mRNA), allowing the translation of replicase/transcriptase and viral structural proteins. The replicase/transcriptase genes account for approximately 2/3 of the 5'-end RNA sequence and are composed of two overlapping open reading frames (ORFs): ORF1a and ORF1b. The ORFs encode 16 non-structural proteins. The remaining 1/3 of the RNA sequence encodes four classical viral structural proteins, namely, spike (S) protein, envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein. In addition, genes encoding some viral accessory proteins are interspersed in the coding regions of the viral structural proteins. The coding sites and number of these accessory protein genes are an important basis for CoV classification. CoVs can infect a variety of host species, including birds, humans and some other vertebrates. These viruses mainly cause respiratory and intestinal infections and induce a variety of clinical manifestations.^{6,7}

Coronaviruses have long been recognized as important pathogens that infect the respiratory tracts of domestic and companion animals and are the causes of mild and severe respiratory

* Corresponding author.

E-mail address: maojh88@zju.edu.cn (J. Mao).

diseases in humans.^{7,8} So far, seven HCoVs that can invade humans have been identified, including the α -type HCoV-229E and HCoV-NL63; the β -type HCoV-HKU1, SARS-CoV, MERS-CoV, and HCoV-OC43; and 2019-nCoV, causing the present epidemic. According to their pathogenicity, HCoVs are divided into mildly pathogenic HCoVs (including HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1) and highly pathogenic CoVs (including severe acute respiratory syndrome CoV (SARS-CoV),⁹ Middle East respiratory syndrome coronavirus (MERS-CoV)^{10,11} and SARS-CoV-2). The mildly pathogenic HCoVs infect the upper respiratory tract and cause seasonal, mild to moderate cold-like respiratory diseases in healthy individuals. In contrast, the highly pathogenic HCoVs (hereinafter referred to as pathogenic HCoVs or HCoVs) infect the lower respiratory tract and cause severe pneumonia, sometimes leading to fatal acute lung injury (ALI) and ARDS. The pathogenic HCoVs have high morbidity and mortality and pose a major threat to public health.^{12–14}

Mechanism of cytokine storm by pathogenic HCoV infection

It has long been believed that cytokines play an important role in immunopathology during viral infection. A rapid and well-coordinated innate immune response is the first line of defense against viral infection. However, dysregulated and excessive immune responses may cause immune damage to the human body.^{15–17} The relevant evidences from severely ill patients with HCoVs suggest that proinflammatory responses play a role in the pathogenesis of HCoVs. *In vitro* cell experiments show that delayed release of cytokines and chemokines occurs in respiratory epithelial cells, dendritic cells (DCs), and macrophages at the early stage of SARS-CoV infection. Later, the cells secrete low levels of the antiviral factors interferons (IFNs) and high levels of proinflammatory cytokines (interleukin (IL)-1 β , IL-6, and tumor necrosis factor (TNF)) and chemokines (C-C motif chemokine ligand (CCL)-2, CCL-3, and CCL-5).^{18–20} Like SARS, MERS-CoV infects human airway epithelial cells, THP-1 cells (a monocyte cell line), human peripheral blood monocyte-derived macrophages and DCs, and induces delayed but elevated levels of proinflammatory cytokines and chemokines.^{21,22} After MERS-CoV infection, plasmacytoid dendritic cells, but not mononuclear macrophages and DCs,²³ are induced to produce a large amount of IFNs.

Serum cytokine and chemokine levels are significantly higher in patients with severe MERS than patients with mild to moderate MERS.^{24,25} The elevated serum cytokine and chemokine levels in MERS patients are related to the high number of neutrophils and monocytes in the patients' lung tissues and peripheral blood, suggesting that these cells may play a role in lung pathology.^{24–26} Similar phenomena have been observed in patients with SARS-CoV infection.^{27–34} The production of IFN-I or IFN- α/β is the key natural immune defense response against viral infections, and IFN-I is the key molecule that plays an antiviral role in the early stages of viral infection.^{35,36} Delayed release of IFNs in the early stages of SARS-CoV and MERS-CoV infection hinders the body's antiviral response.³⁶ Afterward, the rapidly increased cytokines and chemokines attract many inflammatory cells, such as neutrophils and monocytes, resulting in excessive infiltration of the inflammatory cells into lung tissue and thus lung injury. It appears from these studies that dysregulated and/or exaggerated cytokine and chemokine responses by SARS-CoV-infected or MERS-CoV-infected cells could play an important role in pathogenesis of SARS or MERS.

Animal models can well elucidate the role of cytokines and chemokines in mediating pulmonary immunopathology after HCoV infection. Despite of similar virus titers in the respiratory tract, SARS-CoV-infected old nonhuman primates are more likely to develop immune dysregulation than the infected young primates,

leading to more severe disease manifestations.³⁷ It seems that the excessive inflammatory response rather than the virus titer is more relevant to the death of the old nonhuman primates.³⁷ Similarly, in BALB/c mice infected with SARS-CoV, disease severity in old mice is related to the early and disproportionately strong up-regulation of the ARDS-related inflammatory gene signals.³⁸ The rapid replication of SARS-CoV in BALB/c mice induces the delayed release of IFN- α/β , which is accompanied by the influx of many pathogenic inflammatory mononuclear macrophages.¹⁵ The accumulated mononuclear macrophages receive activating signals through the IFN- α/β receptors on their surface and produce more monocyte chemoattractants (such as CCL2, CCL7, and CCL12), resulting in the further accumulation of mononuclear macrophages. These mononuclear macrophages produce elevated levels of proinflammatory cytokines (TNF, IL-6, IL-1 β , and inducible nitric oxide synthase), thereby increasing the severity of the disease. Depleting inflammatory monocyte-macrophages or neutralizing the inflammatory cytokine TNF protected mice from the fatal SARS-CoV infection. In addition, IFN- α/β or mononuclear macrophage-derived proinflammatory cytokines induce the apoptosis of T cells, which further hinders viral clearance.¹⁵ Another consequence of rapid viral replication and vigorous proinflammatory cytokine/chemokine response is the induction of apoptosis in lung epithelial and endothelial cells. IFN- $\alpha\beta$ and IFN- γ induce inflammatory cell infiltration through mechanisms involving Fas-Fas ligand (FasL) or TRAIL-death receptor 5 (DR5) and cause the apoptosis of airway and alveolar epithelial cells.^{39–41} Apoptosis of endothelial cells and epithelial cells damages the pulmonary microvascular and alveolar epithelial cell barriers and causes vascular leakage and alveolar edema, eventually leading to hypoxia in the body. Therefore, inflammatory mediators play a key role in the pathogenesis of ARDS.

ARDS is the leading cause of death in patients infected with SARS-CoV or MERS-CoV.^{42,43} It is now known that several proinflammatory cytokines (IL-6, IL-8, IL-1 β , granulocyte-macrophage colony-stimulating factor, and reactive oxygen species) and chemokines (such as CCL2, CCL-5, IFN γ -induced protein 10 (IP-10), and CCL3) all contribute to the occurrence of ARDS.^{44–46} These results support such points of view that, following SARS-CoV infection, high virus titers and dysregulation of cytokine/chemokine response cause an inflammatory cytokine storm. The inflammatory cytokine storm is accompanied by immunopathological changes in the lungs.

The relationship between cytokine levels and disease progression in patients

High levels of expression of IL-1B, IFN- γ , IP-10, and monocyte chemoattractant protein 1 (MCP-1) have been detected in patients with COVID-19. These inflammatory cytokines may activate the T-helper type 1 (Th1) cell response.⁴⁷ Th1 activation is a key event in the activation of specific immunity.⁴⁸ However, unlike SARS patients, patients with COVID-19 also have elevated levels of Th2 cell-secreted cytokines (such as IL-4 and IL-10), which inhibit the inflammatory response. The serum levels of IL-2R and IL-6 in patients with COVID-19 are positively correlated with the severity of the disease (i.e., critically ill patients > severely ill patients > ordinary patients).⁴⁹ Other studies have found that, compared with COVID-19 patients from general wards, patients in the intensive care unit (ICU) display increased serum levels of granulocyte colony-stimulating factor, IP-10, MCP-1, macrophage inflammatory protein-1A, and TNF- α . The above studies suggest that the cytokine storm is positively correlated with disease severity.⁴⁷

A report on the severe new-type coronavirus-infected pneumonia showed that 37 patients (71.2%) required mechanical ventilation, and 35 patients (67.3%) suffered ARDS. Moreover, the mortality of the elderly patients with ARDS was significantly elevated.⁵⁰

The core pathological change in ARDS is the pulmonary and interstitial tissue damage caused by nonspecific inflammatory cell infiltration.⁵¹ Local excessive release of cytokines is the decisive factor that induces this pathological change and clinical manifestation.⁵² In COVID-19, the inflammatory cytokine storm is closely related to the development and progression of ARDS. The serum levels of cytokines are significantly increased in patients with ARDS, and the degree of increase is positively correlated with mortality rate.⁵³ The cytokine storm is also a key factor in determining the clinical course of extrapulmonary multiple-organ failure.⁵⁴ This partially explains the signs of extrapulmonary organ failure (such as elevated liver enzymes and creatinine) seen in some COVID-19 patients without respiratory failure, suggesting that the inflammatory cytokine storm is the cause of damage to extrapulmonary tissues and organs.

In summary, the new-type coronavirus infection causes an inflammatory cytokine storm in patients. The cytokine storm leads to ARDS or extrapulmonary multiple-organ failure and is an important factor that causes COVID-19 exacerbation or even death.

Theoretical treatment strategy with inflammatory cytokine storm

High virus titer and the subsequent strong inflammatory cytokine and chemokine responses are related to the high morbidity and mortality observed during the pathogenic HCoV infection. The experience from treating SARS and MERS shows that reducing viral load through interventions in the early stages of the disease and controlling inflammatory responses through immunomodulators are effective measures to improve the prognosis of HCoV infection.^{55–58}

IFN- λ

IFN- λ primarily activates epithelial cells and reduces the mononuclear macrophage-mediated proinflammatory activity of IFN- $\alpha\beta$.⁵⁹ In addition, IFN- λ inhibits the recruitment of neutrophils to the sites of inflammation.⁶⁰ SARS-CoV and MERS-CoV mainly infect alveolar epithelial cells (AEC). IFN- λ activates the antiviral genes in epithelial cells, thereby exerting antiviral effects without overstimulating the human immune system. Therefore, IFN- λ may be an ideal treatment. Some studies have applied pegylated and non-pegylated interferons for the treatment of HCoVs, but the efficacy varied significantly due to the application of different treatment regimens. Early administration of interferons has certain benefits in reducing viral load and improves the clinical symptoms of patients to a certain extent. However, it fails to reduce mortality rates.^{61–63} With the exception of early administration, the use of interferons at other time periods will not bring more benefits than placebo treatment.⁶³

Corticosteroid therapies

Corticosteroids are a class of steroid hormones that have anti-inflammatory functions. Corticosteroids are commonly used to suppress inflammation. During the 2003 SARS epidemic, corticosteroids were the primary means of immunomodulation. Timely administration of corticosteroids often leads to early improvements such as reducing fever, relieving radiation infiltration of the lung, and improving oxygenation.^{64–66} A retrospective study of 401 patients with severe SARS revealed that proper administration of glucocorticoids in patients with severe SARS significantly reduced the mortality rate and shortened the hospital stay. Moreover, secondary infections and other complications rarely occurred in these glucocorticoid-treated patients.⁶⁷ However, there are studies showing that administration of corticosteroid therapy during human

SARS-CoV infection led to adverse consequences. Early treatment of SARS patients with corticosteroids increased plasma viral load in non-ICU patients, resulting in the aggravation of the disease.⁶⁴

In treatment of patients with COVID-19, the use of glucocorticoids has again become a major conundrum for clinicians.⁶⁸ The timing of administration and the dosage of glucocorticoids are very important to the outcome of the severely ill patients. A too early administration of glucocorticoids inhibits the initiation of the body's immune defense mechanism, thereby increasing the viral load and ultimately leading to adverse consequences. Therefore, glucocorticoids are mainly used in critically ill patients suffering inflammatory cytokine storm. Inhibition of excessive inflammation through timely administration of glucocorticoids in the early stage of inflammatory cytokine storm effectively prevents the occurrence of ARDS and protects the functions of the patients' organs. For patients with progressive deterioration of oxygenation indicators, rapid imaging progress, and excessive inflammatory response, the use of glucocorticoid in the short term (3–5 days) is appropriate, and the recommended dose is no more than equivalent to methylprednisolone 1–2 mg/kg/day.⁶⁹ It should be noted that large doses of glucocorticoid may delay the clearance of coronavirus due to immunosuppression.

Intravenous immunoglobulin (IVIG)

Chen et al. analyzed the treatment of 99 Wuhan patients with COVID-19 and found that 27% of these patients had received IVIG treatment.⁷⁰ IVIG therapy has the dual effects of immune substitution and immunomodulation. Its practical application value in treatment of COVID-19 needs confirmation in future studies.

IL-1 family antagonists

During the cytokine storm, the three most important cytokines in the IL-1 family are IL-1 β , IL-18, and IL-33.⁴ Studies that focus on the inhibition of IL-1 β to reduce the cytokine storm have attracted most attention. Anakinra, an antagonist of IL-1 β , can be used to treat the cytokine storm caused by infection. It significantly improved the 28-day survival rate of patients with severe sepsis.⁷¹ There is currently no clinical experience with applying specific IL-1 family blockers to treat COVID-19. Their effects need to be verified through *in vivo* animal experiments and clinical trials.

IL-6 antagonists

Tocilizumab is an IL-6 antagonist that suppresses the function of the immune system. Currently, tocilizumab is mainly applied in autoimmune diseases such as rheumatoid arthritis.⁷² Tocilizumab itself has a therapeutic effect on the infection-induced cytokine storm.⁷³ Serum IL-6 level is significantly increased in severely ill patients with COVID-19. Clinical studies from China have shown that Tocilizumab is effective in treating severely ill patients with extensive bilateral lung lesions, who have elevated IL-6 levels. The first dose was 4–8 mg/kg. The recommended dosage was 400mg with 0.9% saline diluted to 100 ml. The infusion time was more than 1 h. For patients with poor efficacy of the first dose, an additional dose can be applied after 12 h (the dose is the same as before), with a maximum of two cumulative dose.

TNF blockers

TNFs are key inflammatory factors that trigger a cytokine storm. They are attractive targets for controlling the cytokine storm. A meta-analysis showed that anti-TNF therapy has significantly improved survival in patients with sepsis.⁷⁴ Anti-TNF therapy has also achieved satisfactory outcomes in treatment of noninfectious

diseases such as atherosclerosis.⁷⁵ Studies in animal models have shown that TNFs contribute significantly to acute lung injury and impair the T cell response in SARS-CoV-challenged mice. In mice, neutralization of TNF activity or loss of TNF receptor provides protection against SARS-CoV-induced morbidity and mortality.^{15,76} However, it should be noted that, at least in the later stages of infection, TNF has not been detected in the serum of patients with SARS. At present, TNF blockers have not been suggested in the treatment of patients with COVID-19, but the efficacy of TNF blockers in treatment of patients with COVID-19 deserves further exploration.

IFN- $\alpha\beta$ inhibitors

IFN- $\alpha\beta$ limits viral replication by inducing IFN-stimulated gene. However, IFN- $\alpha\beta$ also exacerbates diseases through enhancing the recruitment and function of mononuclear macrophages and other innate immune cells. Although an early interferon response has a protective effect on mice infected with SARS-CoV, delayed IFN- $\alpha\beta$ signaling causes an imbalance of the anti-SARS-CoV immune responses in humans. This phenomenon indicates that the timing of IFN treatment is crucial to the outcome of diseases. Based on these results, IFN- $\alpha\beta$ receptor blockers or antagonists should be administered in the later stages of severe disease to prevent excessive inflammatory responses.¹⁶

Chloroquine

Chloroquine inhibits the production and release of TNF and IL-6, which indicates that chloroquine may suppress the cytokine storm in patients infected with COVID-19.⁷⁷ Chloroquine phosphate has been used in the treatment of adults aged 18 to 65 in China.⁷⁸ The recommended dosage by diagnosis and treatment of new coronavirus pneumonia (trial version 7) from China is as follows: If the weight is more than 50 kg, 500 mg each time, 2 times a day, 7 days as a treatment course; If the weight is less than 50 kg, 500 mg each time on the first and second days, twice a day, 500 mg each time on the third to seventh days, once a day.

Ulinastatin

Ulinastatin is a natural anti-inflammatory substance in the body. It protects the vascular endothelium by inhibiting the production and release of inflammatory mediators. Ulinastatin is widely used in clinical practice to treat pancreatitis and acute circulatory failure. Ulinastatin reduces the levels of proinflammatory factors such as TNF- α , IL-6, and IFN- γ , and increases the level of anti-inflammatory factor IL-10.⁷⁹ These activities of ulinastatin promote the balance between proinflammatory and anti-inflammatory responses in humans, thus interrupting the cytokine storm induced by the vicious cycle of inflammation. Animal studies show that the anti-inflammatory effect of high-dose ulinastatin is equivalent to that of hormones.⁸⁰ However, unlike glucocorticoids, ulinastatin does not inhibit immune functions and is unlikely to cause sequelae such as femoral head necrosis. Therefore, ulinastatin has great application prospects in the treatment of COVID-19.

The inhibitory effect of oxidized phospholipids (OxPL)

In a mouse model of influenza A virus (IAV) infection, OxPL increases the production of cytokines/chemokines in lung macrophages through the Toll-like receptor 4 (TLR4)-TIR-domain-containing adapter-inducing interferon- β signaling pathway, thereby promoting the occurrence of ALI.⁸¹ Eritoran is a TLR4 antagonist. It does not have direct antiviral activity but has strong immunomodulatory functions. Eritoran effectively lowers the

production of OxPL, inflammatory cytokines, and chemokines in IAV-infected mice, thereby reducing death.⁸² Pathogenic human coronaviruses also cause a high accumulation of OxPL in patients' lung tissues, resulting in ALI.⁸¹ Thus, it seems that eritoran and other OxPL inhibitors may also be able to alleviate HCoV-induced inflammatory responses.

Sphingosine-1-phosphate receptor 1 agonist therapy

Sphingosine-1-phosphate (S1P) is a signal lysophospholipid that promotes cytokine synthesis and secretion.⁸³ The S1P receptor signaling pathways significantly inhibit the pathological damage induced by the host's innate and adaptive immune responses, thereby reducing the cytokine storm caused by influenza virus infection.^{84,85} In mouse models of IAV infection, sphingosine-1-phosphate receptor 1 (S1P₁) signal transduction in respiratory endothelial cells modulates pathogenic inflammatory responses.⁸⁵ Agonists targeting S1P₁ inhibit excessive recruitment of inflammatory cells, inhibit proinflammatory cytokines and chemokines, and reduce the morbidity and mortality of IAV.^{85,86} SARS-CoV-2 also mainly infects human lung epithelial cells and endothelial cells. Therefore, S1P₁ agonists may be potential therapeutic drugs for reducing cytokine and chemokine responses in those HCoV patients whose cells generated excessive immune responses. An S1P-receptor modulating drug, siponimod, was approved in 2019 to treat multiple sclerosis. However, clinical trials are needed to further verify whether siponimod is an ideal alternative for the treatment of cytokine storm.

Stem cell therapy

As an important member of the stem cell family, mesenchymal stem cells (MSC) not only have the potential of self-renewal and multidirectional differentiation, but also have strong anti-inflammatory and immune regulatory functions. MSC can inhibit the abnormal activation of T lymphocytes and macrophages, and induce their differentiation into regulatory T cell (Treg) subsets and anti-inflammatory macrophages, respectively. It can also inhibit the secretion of pro-inflammatory cytokines, such as, IL-1, TNF- α , IL-6, IL-12, and IFN- γ , thereby reducing the occurrence of cytokine storms.^{87,88} At the same time, MSC can secrete IL-10, hepatocyte growth factor, keratinocyte growth factor and VEGF to alleviate ARDS, regenerate and repair damaged lung tissues, and resist fibrosis.⁸⁹ Therefore, many functions of MSC are expected to make it an effective method for the treatment of COVID-19.

Blood purification treatments

In addition, the blood purification treatments currently used in clinic practice can remove inflammatory factors to a certain extent. Blood purification system including plasma exchange, adsorption, perfusion, blood/plasma filtration, etc., can remove inflammatory factors, block the "cytokine storm", to reduce the damage of inflammatory response to the body. This therapy can be used for severe and critical patients in the early and middle stages of the disease. The artificial liver technology led by Academician Li Lanjuan can eliminate inflammatory factors on a large scale. This technology has also been used to resist the cytokine storm of H7N9, and its application on COVID-19 has also achieved certain efficacy.⁹⁰ Early renal replacement therapy, which is similar to the treatment principle of artificial liver technology, seems to be an effective method to control cytokine storm.⁹¹




Fig. 1. Mechanism of cytokine storm in COVID-19 and potential therapy.

① Supplement with IFN- λ to activate the innate immunity; ② Using immunomodulator to restore immune balance; ③ Inhibiting the production of cytokines; ④ Scavenging cytokines; ⑤ Inhibiting mononuclear macrophage recruitment and function; ⑥ Strengthening the vascular barrier by activating of the endothelial Slit-Robo4 signal pathway.

Inhibitors of mononuclear macrophage recruitment and function

An autopsy report of patients with COVID-19 revealed a large amount of inflammatory cell infiltration in the lungs of the deceased.⁹² One potentially effective treatment approach is to reduce the recruitment of mononuclear macrophages to the site of inflammation through small interfering RNA (siRNA)-mediated silencing of C-C chemokine receptor type 2 (CCR2), which has been demonstrated by animal experiments to improve the outcome of the disease.^{93,94} Toll-like receptor 7 (TLR7) agonists stimulate mononuclear macrophages to undergo a strong inflammatory response at the time of infection with single-stranded RNA (ssRNA) viruses such as HCoV. Therefore, TLR7 antagonists may be able to alleviate the storm of inflammatory factors caused by SARS-CoV-2 infection.

Strengthens the vascular barrier

Increased vascular permeability is also a hallmark change that occurs in the process of a cytokine storm. It was found in animal infection models of sepsis and H5N1 virus that activation of the endothelial Slit-Robo4 pathway with drugs improved vascular permeability, thereby reducing the occurrence of a cytokine storm during infection.⁹⁵

Conclusion

Inflammation is an essential part of an effective immune response. It is difficult to eliminate infections successfully without inflammation. The inflammatory response begins with an initial recognition of pathogens. The pathogens then mediate the recruitment of immune cells, which eliminates the pathogens and ultimately leads to tissue repair and restoration of homeostasis. However, SARS-CoV-2 induces excessive and prolonged cytokine/chemokine responses in some infected individuals, known as the cytokine storm. Cytokine storm causes ARDS or multiple-organ dysfunction, which leads to physiological deterioration and death. Timely control of the cytokine storm in its early stage through such means as immunomodulators and cytokine antagonists, as well as the reduction of lung inflammatory cell infiltration, is the key to improving the treatment success rate and reducing the mortality rate of patients with COVID-19. Fig. 1

Declaration of Competing Interest

The authors declare that they have no competing financial interests.

Contributors

QY led the writing of the manuscript. JHM developed the initial concept and framework for the manuscript and oversaw the drafting of the manuscript. All authors contributed to the content, drafting, and critical review of the manuscript.

Funding

This study was supported by Zhejiang University special scientific research fund for COVID-19 prevention and control.

References

- Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents* 2020;105924 2020/02/17/.
- Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19). *Chin J Epidemiol* 2020;41.
- Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. *Seminars Immunopathol* 2017;**39**(5):517–28 2017/07/01.
- Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. *J Immunotherapy Cancer* 2018;**6**(1):56 2018/06/15.
- Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). 2020:medRxiv2020.02.10.20021832.
- Peck KM, Burch CL, Heise MT, Baric RS. Coronavirus host range expansion and middle east respiratory syndrome coronavirus emergence: biochemical mechanisms and evolutionary perspectives. *Ann Rev Virol* 2015;**2**(1):95–117 PubMed PMID: 26958908. Epub 2015/08/07. eng.
- Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. *Trends Microbiol Jun* 2016;**24**(6):490–502 PubMed PMID: 27012512. Epub 2016/03/26. eng.
- Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. *Microbiol Mol Biol Rev Dec* 2005;**69**(4):635–64 PubMed PMID: 16339739. Pubmed Central PMCID: PMC1306801. Epub 2005/12/13. eng.
- Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. *Nature Rev Microbiol* 2009;**7**(6):439–50 PubMed PMID: 19430490. eng.
- Heugel J, Martin ET, Kuypers J, Englund JA. Coronavirus-associated pneumonia in previously healthy children. *Pediatr Infect Disease J* 2007;**26**(8):753–5 PubMed PMID: 17848893. eng.
- Kuypers J, Martin ET, Heugel J, Wright N, Morrow R, Englund JA. Clinical disease in children associated with newly described coronavirus subtypes. *Pediatrics* 2007;**119**(1):e70–ee6 PubMed PMID: 17130280. Epub 2006/11/27. eng.
- Kuiken T, Fouchier RAM, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. *Lancet* 2003;**362**(9380):263–70 (London, England)/PubMed PMID: 12892955. eng.
- Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* 2003;**361**(9366):1319–25 (London, England)/PubMed PMID: 12711465. eng.
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *Engl J Med* 2012;**367**(19):1814–20 PubMed PMID: 23075143. Epub 2012/10/17. eng.
- Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I Interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-Infected Mice. *Cell Host Microbe* 2016;**19**(2):181–93 PubMed PMID: 26867177. eng.
- Davidson S, Maini MK, Wack A. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. *J Interf Cytokine Res Off J Int Soc Interf Cytokine Res* 2015;**35**(4):252–64 PubMed PMID: 25714109. Epub 2015/02/25. eng.
- Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. *Nature Rev Immunol* 2013;**13**(12):875–87 PubMed PMID: 24157572. Epub 2013/10/25. eng.
- Law HKW, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. *Blood* 2005;**106**(7):2366–74 PubMed PMID: 15860669. Epub 2005/04/28. eng.
- Cheung CY, Poon LLM, Ng IHY, Luk W, Sia S-F, Wu MHS, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. *J Virol* 2005;**79**(12):7819–26 PubMed PMID: 15919935. eng.
- Lau SKP, Lau CCY, Chan K-H, Li CPY, Chen H, Jin D-Y, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. *J Gen Virol* 2013;**94**(Pt 12):2679–90 PubMed PMID: 24077366. Epub 2013/09/28. eng.
- Tynell J, Westenius V, Rönkkö E, Munster VJ, Melén K, Österlund P, et al. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. *J Gen Virol* 2016;**97**(2):344–55 PubMed PMID: 26602089. Epub 2015/11/24. eng.
- Zhou J, Chu H, Li C, Wong BH-Y, Cheng Z-S, Poon VK-M, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. *J Infect Diseases* 2014;**209**(9):1331–42 PubMed PMID: 24065148. Epub 2013/09/24. eng.
- Scheuplein VA, Seifried J, Malczyk AH, Miller L, Höcker L, Vergara-Alert J, et al. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. *J Virol* 2015;**89**(7):3859–69 PubMed PMID: 25609809. Epub 2015/01/21. eng.
- Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY, et al. Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection. *J Korean Med Sci* 2016;**31**(11):1717–25 PubMed PMID: 27709848. eng.
- Min C-K, Cheon S, Ha N-Y, Sohn KM, Kim Y, Aigerim A, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. *Scient Rep* 2016;**6**:25359 PubMed PMID: 27146253. eng.
- Ng DL, Al Hosani F, Keating MK, Gerber SI, Jones TL, Metcalfe MG, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of middle east respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. *Am J Pathol* 2016;**186**(3):652–8 PubMed PMID: 26857507. Epub 2016/02/05. eng.
- JY C, PR H, WC C, CJ Y, PC Y. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. *Respirol (Carlton, Vic)* 2006;**11**(6):715–22 PubMed PMID: 17052299.
- CH W, CY L, YL W, CL C, KH H, HC L, et al. Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. *Respirat Res* 2005;**6**:42 PubMed PMID: 15888207.
- CK W, CW L, AK W, WK I, NL L, IH C, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exper Immunol* 2004;**136**(1):95–103 PubMed PMID: 15030519.
- Y Z, J L, Y Z, L W, X Y, W Z, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. *Infect Immun* 2004;**72**(8):4410–15 PubMed PMID: 15271897.
- Chien J-Y, Hsueh P-R, Cheng W-C, Yu C-J, Yang P-C. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. *Respirol (Carlton, Vic)* 2006;**11**(6):715–22 PubMed PMID: 17052299. eng.
- Wang C-H, Liu C-Y, Wan Y-L, Chou C-L, Huang K-H, Lin H-C, et al. Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. *Respirat Res* 2005;**6**(1):42 -. PubMed PMID: 15888207. eng.
- Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clinical Exper Immunol* 2004;**136**(1):95–103 PubMed PMID: 15030519. eng.
- Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. *Infect Immun* 2004;**72**(8):4410–15 PubMed PMID: 15271897. eng.
- A G-S, CA B. Type 1 interferons and the virus-host relationship: a lesson in détente. *Science* 2006;**312**(5775):879–82 (New York, NY)/PubMed PMID: 16690858.
- R C, AR F, J Z, C W-L, JE A, M M, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. *J Clin Invest* 2019;**130**:3625–39 PubMed PMID: 31355779.
- Smits SL, de Lang A, van den Brand JMA, Leijten LM, van Ijcken WF, Eijkemans MJC, et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. *PLoS Pathogens* 2010;**6**(2) e1000756-e. PubMed PMID: 20140198. eng.
- Rockx B, Baas T, Zornetzer GA, Haagsmans B, Sheahan T, Frieman M, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. *J Virol* 2009;**83**(14):7062–74 PubMed PMID: 19420084. Epub 2009/05/06. eng.
- Herold S, Steinmueller M, von Wulffen W, Cakarova L, Pinto R, Pleschka S, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. *J Exper Med* 2008;**205**(13):3065–77 PubMed PMID: 19064696. Epub 2008/12/08. eng.
- Högner K, Wolff T, Pleschka S, Plog S, Gruber AD, Kalinke U, et al. Macrophage-expressed IFN- β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. *PLoS Pathogens* 2013;**9**(2) e1003188-e. PubMed PMID: 23468627. Epub 2013/02/28. eng.
- Rodrigue-Gervais IG, Labbé K, Dagenais M, Dupaul-Chicoine J, Champagne C, Morizot A, et al. Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival. *Cell Host Microbe* 2014;**15**(1):23–35 PubMed PMID: 24439895. eng.
- Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. *Lancet Infect Diseases* 2013;**13**(9):745–51 PubMed PMID: 23782859. Epub 2013/06/17. eng.
- Lew TWK, Kwek T-K, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. *JAMA* 2003;**290**(3):374–80 PubMed PMID: 12865379. eng.

44. Jiang Y, Xu J, Zhou C, Wu Z, Zhong S, Liu J, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. *Am J Respir Crit Care Med* 2005;**171**(8):850–7 PubMed PMID: 15657466. Epub 2005/01/18. eng.
45. Reghunathan R, Jayapal M, Hsu L-Y, Chng H-H, Tai D, Leung BP, et al. Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. *BMC Immunol* 2005;**6**:2 -. PubMed PMID: 15655079. eng.
46. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). *Virus Res* 2008;**133**(1):13–19 PubMed PMID: 17374415. Epub 2007/03/19. eng.
47. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;**395**(10223):497–506 2020/02/15/.
48. Marchingo JM, Sinclair LV, Howden AJM, Cantrell DA. Quantitative analysis of how Myc controls T cell proteomes and metabolic pathways during T cell activation. *eLife*. 2020;**9**:e53725 2020/02/05.
49. Chen L, Liu H-G, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. *Chin J Tuberc Respir Dis* 2020;**43**.
50. Yang X, Yu Y, Xu J, Shu H, Ja Xia, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020 S2213-600(20)30079-5. PubMed PMID: 32105632. eng.
51. Force* TADT Acute respiratory distress syndrome: the berlin definition. *JAMA* 2012;**307**(23):2526–33.
52. Douda DN, Jackson R, Grasemann H, Palaniyar N. Innate immune collectin surfactant protein D simultaneously binds both neutrophil extracellular traps and carbohydrate ligands and promotes bacterial trapping. *J Immunol (Baltimore, Md: 1950)* 2011;**187**(4):1856–65 PubMed PMID: 21724991. Epub 2011/07/01. eng.
53. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. *Critical Care Med* 2005;**33**(1):1–232 PubMed PMID: 15644641. eng.
54. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. *Am J Emerg Med* 2008;**26**(6):711–15 PubMed PMID: 18606328. eng.
55. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006;**3**(9):e343-e. PubMed PMID: 16968120. eng.
56. Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. *Clinical Infect Diseases Offic Publ Infect Diseases Soc Am* 2019 ciz544. PubMed PMID: 31925415. eng.
57. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon- α 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. *Nature Med* 2013;**19**(10):1313–17 PubMed PMID: 24013700. Epub 2013/09/08. eng.
58. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. *Lancet Infect Diseases* 2014;**14**(11):1090–5 PubMed PMID: 25278221. Epub 2014/09/29. eng.
59. Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, et al. IFN λ is a potent anti-influenza therapeutic without the inflammatory side effects of IFN α treatment. *EMBO Mol Med* 2016;**8**(9):1099–112 PubMed PMID: 27520969. eng.
60. Blazeck K, Eames HL, Weiss M, Byrne AJ, Perocheau D, Pease JE, et al. IFN- λ resolves inflammation via suppression of neutrophil infiltration and IL-1 β production. *J Exper Med* 2015;**212**(6):845–53 PubMed PMID: 25941255. Epub 2015/05/04. eng.
61. Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. *Clinical Infect Diseases* 2019.
62. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. *Lancet Infect Diseases* 2014;**14**(11):1090–5 2014/11/01/.
63. Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen K-Y. Coronaviruses – drug discovery and therapeutic options. *Nature Rev Drug Discov* 2016;**15**(5):327–47 2016/05/01.
64. Auyeung TW, Lee JSW, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. *J Infect* 2005;**51**(2):98–102 PubMed PMID: 16038758. eng.
65. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. *Am J Resp Crit Care Med* 2003;**168**(12):1449–56 PubMed PMID: 12947028. Epub 2003/08/28. eng.
66. Yam LY-C, Lau AC-W, Lai FY-L, Shung E, Chan J, Wong V, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. *J Infect* 2007;**54**(1):28–39 PubMed PMID: 16542729. Epub 2006/03/15. eng.
67. Chen R-c, Tang X-p, Tan S-y, Liang B-l, Wan Z-y, Fang J-q, et al. Treatment of Severe Acute Respiratory Syndrome With Glucocorticoids: The Guangzhou Experience. *Chest* 2006;**129**(6):1441–52 2006/06/01/.
68. Zhao J-p, Hu Y, Du R-h, Chen Z-s, Jin Y, Zhou M, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. *Chin J Tuberc Respir Dis* 2020(00) E007-E. chi.
69. Zhou Y-H, Qin Y-Y, Lu Y-Q, Sun F, Yang S, Harypursat V, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. *Chin Med J* 2020(00) E020-E. chi.
70. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;**395**(10223):507–13 2020/02/15/.
71. Shakoori B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. *Critical Care Med* 2016;**44**(2):275–81 PubMed PMID: 26584195. eng.
72. Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. *Drug Design, Devel Therap* 2018;**13**:57–70 PubMed PMID: 30587928. eng.
73. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. *Immunotherapy* 2016;**8**(8):959–70 PubMed PMID: 27381687. eng.
74. Qiu P, Cui X, Sun J, Welsh J, Natanson C, Eichacker PQ. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. *Critical Care Med* 2013;**41**(10):2419–29 PubMed PMID: 23887234. eng.
75. Udaloa I, Monaco C, Nanchahal J, Feldmann M. Anti-TNF Therapy. *Microbiol Spect* 2016;**4**(4).
76. McDermott JE, Mitchell HD, Gralinski LE, Eisfeld AJ, Josset L, Bankhead A, et al. The effect of inhibition of PP1 and TNF α signaling on pathogenesis of SARS coronavirus. *BMC Syst Biol* 2016;**10**(1):93 -. PubMed PMID: 27663205. eng.
77. J G, Z T, X Y. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends* 2020;**14**(1):72–3 PubMed PMID: 32074550.
78. multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. *Chinese J Tuberc Respir Diseases* 2020;**43** E019-E. PubMed PMID: 32075365.
79. H W, B L, Y T, P C, L Y, B H, et al. Improvement of sepsis prognosis by Ulinastatin: a systematic review and meta-analysis of randomized controlled trials. *Frontiers Pharmacol* 2019;**10**:1370 PubMed PMID: 31849646.
80. M J, H H, S C, Y L, Y L, S P, et al. Ulinastatin ameliorates LPS-induced pulmonary inflammation and injury by blocking the MAPK/NF- κ B signaling pathways in rats. *Molecular Med Rep* 2019;**20**(4):3347–54 PubMed PMID: 31432172.
81. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. *Cell* 2008;**133**(2):235–49 PubMed PMID: 18423196. eng.
82. Shirey KA, Perkins DJ, Lai W, Zhang W, Fernando LR, Gusovsky F, et al. Influenza "Trains" the host for enhanced susceptibility to secondary bacterial infection. *mBio*. 2019;**10**(3):e00810–19 PubMed PMID: 31064834. eng.
83. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. *Trends Cell Biol* 2012;**22**(1):50–60 PubMed PMID: 22001186. Epub 2011/10/14. eng.
84. Walsh KB, Teijaro JR, Rosen H, Oldstone MBA. Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. *Immunol Res* 2011;**51**(1):15 2011/09/08.
85. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. *Cell* 2011;**146**(6):980–91 PubMed PMID: 21925319. eng.
86. Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. *Proc Natl Acad Sci USA* 2011;**108**(29):12018–23 PubMed PMID: 21715659. Epub 2011/06/29. eng.
87. Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. *Ann NY Acad Sci* 2015;**1351**(1):114–26.
88. Ben-Mordechai T, Palevski D, Glucksam-Galnoy Y, Elron-Gross I, Margalit R, Leor J. Targeting macrophage subsets for infarct repair. *J Cardiovascular Pharmacol Therapeut* 2014;**20**(1):36–51 2015/01/01.
89. Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. *STEM CELLS* 2011;**29**(6):913–19.
90. K X, H C, Y S, Q N, Y C, S H, et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. *Zhejiang da xue xue bao Yi xue ban* 2020;**49**(1):0 PubMed PMID: 32096367.
91. Zuccari S, Damiani E, Domizi R, Scorcella C, D'Arezzo M, Carsetti A, et al. Changes in cytokines, haemodynamics and microcirculation in patients with sepsis/septic shock undergoing continuous renal replacement therapy and blood purification with cytoSorb. *Blood Purificat* 2020;**49**(1-2):107–13.
92. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020 S2213-600(20)30076-X. PubMed PMID: 32085846. eng.
93. Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbato R, Sena B, et al. Silencing of CCR2 in myocarditis. *Eur Heart J* 2015;**36**(23):1478–88 PubMed PMID: 24950695. Epub 2014/06/20. eng.
94. Leuschner F, Dutta P, Gorbato R, Novobrantseva TI, Donahoe JS, Courties G, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. *Nature Biotechnol* 2011;**29**(11):1005–10 PubMed PMID: 21983520. eng.
95. London NR, Zhu W, Bozza FA, Smith MCP, Greif DM, Sorensen LK, et al. Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm in Sepsis and Influenza. *Sci Transl Med* 2010;**2**(23) 23ra19.